-Company expects to initiate Phase 2 study in 2H 2025- SAN DIEGO, CA, USA I July 30, 2025 I EuMentis Therapeutics, Inc., (“EuMentis”), a clinical-stage drug development company focused on advancing ...

-Data showcased in session titled “Spotlight on Drug Delivery” at the Ophthalmology Innovation Source (OIS) Retina 8 th Annual Innovation Summit -VLTR-559, a long-acting anti-VEGF therapy, could ...

LEIDEN, Netherlands I July 28, 2025 I Azafaros, a company focused on developing treatments for the unmet needs of patients with rare lysosomal storage disorders, today announced that the first patient ...

PITTSBURGH, PA, USA I July 24, 2025 I Jeune Aesthetics, Inc. (“Jeune”), a wholly owned subsidiary of Krystal Biotech, Inc. (“Krystal”) (NASDAQ: KRYS) leveraging Krystal’s clinically validated ...

DURHAM, NC, USA and BEIJING, China I July 3, 2025 I Brii Biosciences Limited (“Brii Bio,” stock code: 2137.HK), a biotechnology company developing therapies to improve patient health and choice across ...

HONG KONG, BEIJING, China and BOSTON, MA, USA I June 6, 2025 I GenEditBio Limited (“GenEditBio”), a clinical-stage biotechnology start-up company focusing on genome editing therapeutic solutions ...

TARRYTOWN, NY, USA I June 2, 2025 I Sapience Therapeutics, Inc., a clinical-stage biotechnology company focused on the discovery and development of peptide therapeutics to address oncogenic and immune ...

– 46% reduction in the risk of disease progression or death, and 27% reduction in the risk of death, in an aggressive cancer type with limited survival and few treatment options – – First Phase III ...

NEW YORK, NY, USA I May 19, 2025 I Pfizer Inc. (NYSE: PFE) today announced it has entered into an exclusive global, ex-China, licensing agreement with 3SBio, Inc. (01530.HK), a leading Chinese ...

Novel glycan-directed ADC shows preclinical activity in gastric cancer and potential to address underserved patient population NEW TAIPEI CITY, Taiwan I April 28, 2025 I GlycoNex, Inc. (4168, ...

WARREN, NJ, USA I November 13, 2024 I PTC Therapeutics, Inc. (NASDAQ: PTCT) announced today the U.S. Food and Drug Administration (FDA) accelerated approval of its gene therapy for the treatment of ...